A practical reference on PPARδ: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Stilton blue cheese was first sold in the village of Stilton in England, but there is little evidence it was ever made there. Stilton cheese is made from pasteurized milk; a similar, less commonly found, blue cheese made from raw milk and without factory-produced rennet is Stichelton. In addition to being inoculated with Penicillium roqueforti to give it the blue vein characteristic, research has shown that other microbiota which are relatives of Lactococcus lactis, Enterococcus faecalis, Lactobacillus plantarum, Latilactobacillus curvatus, Leuconostoc mesenteroides, Staphylococcus equorum, and Staphylococcus sp. can also be found in blue Stilton cheese. Some important microbiota contribute to the aromatic profile such as those of the Lactobacillus genus due to their production of volatile compounds. During ripening, free fatty acids increase in amount, which contributes to the characteristic flavor of blue cheeses due to fat breakdown by Penicillium roqueforti. There is also uninoculated white Stilton cheese.
{\displaystyle {\frac {R}{r}}\geq {\frac {abc+a^{3}+b^{3}+c^{3}}{2abc}}\geq {\frac {a}{b}}+{\frac {b}{c}}+{\frac {c}{a}}-1\geq {\frac {2}{3}}\left({\frac {a}{b}}+{\frac {b}{c}}+{\frac {c}{a}}\right)\geq 2.}
== Further reading == Schroeder, Avi; Honen, Reuma; Turjeman, Keren; Gabizon, Alberto; Kost, Joseph; Barenholz, Yechezkel (2009). "Ultrasound triggered release of cisplatin from liposomes in murine tumors". Journal of Controlled Release. 137 (1): 63–8. doi:10.1016/j.jconrel.2009.03.007. PMID 19303426. Scott, Robert C.; Wang, Bin; Nallamothu, Ramakrishna; Pattillo, Christopher B.; Perez-Liz, Georgina; Issekutz, Andrew; Valle, Luis Del; Wood, George C.; Kiani, Mohammad F. (2007). "Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction". Biotechnology and Bioengineering. 96 (4): 795–802. doi:10.1002/bit.21233. PMID 17051598. S2CID 30039741. Scott, Robert C; Crabbe, Deborah; Krynska, Barbara; Ansari, Ramin; Kiani, Mohammad F (2008). "Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue". Expert Opinion on Drug Delivery. 5 (4): 459–70. doi:10.1517/17425247.5.4.459. PMID 18426386. S2CID 71338475. Wang, Bin; Rosano, Jenna M; Cheheltani, Rabe'e; Achary, Mohan P; Kiani, Mohammad F (2010). "Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer". Expert Opinion on Drug Delivery. 7 (10): 1159–73. doi:10.1517/17425247.2010.513968. PMID 20738211. S2CID 19679654. Wang, Bin; Scott, Robert C.; Pattillo, Christopher B.; Prabhakarpandian, Balabhaskar; Sundaram, Shankar; Kiani, Mohammad F. (2008). "Modeling Oxygenation and Selective Delivery of Drug Carriers Post-Myocardial Infarction". In Kang, Kyung A.; Harrison, David K.; Bruley, Duane F. (eds.). Oxygen Transport to Tissue XXIX.
Levamisole, sold under the brand name Ergamisol among others, is a medication used to treat parasitic worm infections, specifically ascariasis and hookworm infections. It is taken by mouth. Side effects may include abdominal pain, vomiting, headache, and dizziness. Use is not recommended during breastfeeding or the third trimester of pregnancy. Serious side effects may include an increased risk of infection. It belongs to the anthelmintic class of medications. Levamisole was invented in 1966 in Belgium by Janssen Pharmaceuticals. It is on the World Health Organization's List of Essential Medicines. Levamisole is also used as a dewormer for cattle. It is also often used as a cutting agent in illegal cocaine. In February 2026, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended that medicines containing levamisole be withdrawn from the EU market. This follows an EU-wide review which concluded that the benefits of these medicines no longer outweigh their risks for the treatment of parasitic worm infections in adults and children.
Sources: en.wikipedia.org
=== Yeast amino acid metabolism === In 1912 Felix Ehrlich demonstrated that yeast metabolizes the natural amino acids essentially by splitting off carbon dioxide and replacing the amino group with a hydroxyl group. By this reaction, tryptophan gives rise to tryptophol.
Psychedelic microdosing is the practice of using sub-threshold doses (microdoses) of psychedelics in an attempt to improve creativity, boost physical energy level, emotional balance, increase performance on problems-solving tasks and to treat anxiety, depression and addiction. The practice of microdosing has become more widespread in the 21st century with more people claiming long-term benefits from the practice. A 2022 study recognized signatures of psilocybin microdosing in natural language and concluded that low amount of psychedelics have potential for application, and ecological observation of microdosing schedules.
The medals were presented to Cotchin and Mitchell in a small ceremony in Melbourne on 13 December 2016. Watson's physical medal was handed back to the AFL CEO Gillon McLachlan in early 2017, with no plans in place to re-present or display it as of February 2017.
Sources: en.wikipedia.org
=== Regulation === PCP is a Schedule II substance in the US. The Administrative Controlled Substances Code Number (ACSCN) for PCP is 7471. Its manufacturing quota for 2014 was 19 grams (0.67 oz). It is a Schedule I drug by the Controlled Drugs and Substances act in Canada, a List I drug of the Opium Law in the Netherlands, and a Class A substance in the UK.
=== Legal status === Treosulfan was authorized for medical use in the European Union in June 2019, and approved for medical use in the United States in January 2025. The US Food and Drug Administration granted orphan drug designation to treosulfan in 1994, for the treatment of ovarian cancer; and in 2015, for conditioning treatment prior to hematopoietic stem cell transplantation in malignant and non-malignant diseases in adults and pediatric patients. In February 2004, orphan designation (EU/3/04/186) was granted by the European Commission to medac Gesellschaft fuer klinische Spezialpräparate mbH, Germany, for treosulfan for the conditioning treatment prior to haematopoietic progenitor cell transplantation.
=== Biomaterials === Using antibiotic-free alternatives in bone infection treatment may help decrease the use of antibiotics and thus antimicrobial resistance. The bone regeneration material bioactive glass S53P4 has shown to effectively inhibit the bacterial growth of up to 50 clinically relevant bacteria including MRSA and MRSE.
=== Clinical v. mechanical prediction === Clinical assessment can be characterized as a prediction problem where the purpose of assessment is to make inferences (predictions) about past, present, or future behavior. For example, many therapy decisions are made on the basis of what a clinician expects will help a patient make therapeutic gains. Once observations have been collected (e.g., psychological testing results, diagnostic impressions, clinical history, X-ray, etc.), there are two mutually exclusive ways to combine those sources of information to arrive at a decision, diagnosis, or prediction. One way is to combine the data in an algorithmic, or "mechanical" fashion. Mechanical prediction methods are simply a mode of combination of data to arrive at a decision/prediction of behavior (e.g., treatment response). The mechanical prediction does not preclude any type of data from being combined; it can incorporate clinical judgments, properly coded, in the algorithm. The defining characteristic is that, once the data to be combined is given, the mechanical approach will make a prediction that is 100% reliable. That is, it will make exactly the same prediction for exactly the same data every time. Clinical prediction, on the other hand, does not guarantee this, as it depends on the decision-making processes of the clinician making the judgment, their current state of mind, and knowledge base.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.